Author: Ravi Shankar

Series	RIKS 37 0115	RIKS 50 0915
ISIN	IS0000033793	IS0000037794
Maturity Date	01/15/2037	09/15/2050
Auction Date	10/23/2026	10/23/2026
Settlement Date	10/28/2026	10/28/2026
10% addition	10/27/2026	10/27/2026

On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%.

Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website.

For additional information please contact Magnús Freyr Hrafnsson, Government Debt Management, at +354 569 9679.

21 October 2026

HARGREAVE HALE AIM VCT PLC
(the “Company”)

Purchase of shares for cancellation

Hargreave Hale AIM VCT plc announces that on 21 October 2026 the Company purchased 999,037 ordinary shares at a price of 29.93 pence per share for cancellation.

Following the purchase and cancellation of the above shares, 373,146,523 ordinary shares of one pence each will remain in issue, carrying one vote each.  

The Company does not hold any ordinary shares in Treasury. Therefore, the total voting rights in the Company will be 373,146,523.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

END

For further information, please contact:

Canaccord Genuity Asset Management Limited Abbe Martineau

aimvct@canaccord.com +44 20 7523 4525

LEI: 213800LRYA19A69SIT31

In accordance with the press release dated 20 October 2026, the offering of the new Tier 2 Capital Notes was priced and subscribed today with significant demand. Tryg Forsikring A/S has accordingly decided to issue notes for a nominal amount of NOK 400m and SEK 900m (the “Transaction”). The Transaction was more than 2 times oversubscribed at its peak and was placed primarily with Asset Managers and Funds across the Scandinavian countries.

The Transaction will be settled on 30 October 2026. The NOK Notes will have a variable interest rate of 3M NIBOR +115bps per annum and the SEK Notes will have a variable interest rate of 3M STIBOR +115bps per annum. All of the Notes will feature an interest rate step-up of 1.00% per annum from 30 October 2036.

The first interest payment date on the Transaction will be 30 January 2027. The Transaction has scheduled maturity on 30 October 2056, but Tryg Forsikring A/S has the option to prepay the Notes at par on any day from (and including) 30 October 2031 to (and including) 30 January 2032, or on any Interest Payment Date thereafter.

The notes are expected to be listed on Nasdaq Copenhagen.
In connection with the Transaction, Tryg Forsikring A/S will purchase SEK 153m of its outstanding SEK 1,300,000,000 Floating Rate Tier 2 Capital Notes with ISIN DK0030488101 at a price of 100.042%. The purchase is conditional upon certain conditions, including the settlement of the Transaction.

Additional information:
For further information, visit tryg.com tryg.com or contact:

Head of Financial Reporting, Gianandrea Roberti at +45 20 18 82 67 or gianandrea.roberti@tryg.dk
Head of Investor Relations, Robin H. Løfgren at +45 41 86 25 88 or robin.loefgren@tryg.dk

This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction pursuant to the Transaction or otherwise in any jurisdiction in which such offer, invitation or solicitation is unlawful.

This announcement does not constitute a prospectus, prospectus equivalent document or an exempted document.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933 (the “US Securities Act”), as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

About Tryg
Tryg is one of the largest insurance companies in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for more than 6 million customers on a daily basis. Tryg A/S is listed on NASDAQ Copenhagen and approximately 49% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 700m to peace of mind purposes via TrygFonden.

Notice to U.S. investors
This announcement does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the US Securities Act, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements.

Cautionary note about forward-looking statements
This announcement (including any information incorporated by reference in this announcement), oral statements made regarding the Transaction, and other information published by Tryg Forsikring A/S contain statements which are, or may be deemed to be, “forward-looking statements”. Forward looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Tryg Forsikring A/S about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Forward looking statements often use words such as “believe”, “expect”, “estimate”, “intend”, “anticipate” and words of a similar meaning, and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved (or, in each case, their negative or other variations). You should not place undue reliance on these forward looking statements, which reflect the current views of Tryg Forsikring A/S, are subject to risks and uncertainties about Tryg Forsikring A/S and are dependent on many factors, some of which are outside of Tryg Forsikring A/S’ control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different. Except as required by law, Tryg Forsikring A/S undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment

• Tryg Forsikring AS Prices Tier 2 Notes

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on October 23, 2026

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company’s class A ordinary shares and class B ordinary shares.

The Company’s class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on October 23, 2026. The shares will continue to trade under the ticker symbol “PASW.”

At the extraordinary general meeting (the “EGM”) of shareholders of the Company held on 18 March 2026, at 9:00 a.m., Hong Kong Time, the following matters, among others, were approved and authorized that with effect on a date within one (1) calendar year after the conclusion of the EGM to be determined by the board of directors of the Company (the “Board”): (A) every one thousand (1,000) then issued and unissued class A ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class A ordinary share (the “Consolidated Class A Share(s)”), (B) every one thousand (1,000) then issued and unissued class B ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class B ordinary share (the “Consolidated Class B Share(s)”); (C) all fractional entitlements to the issued Consolidated Class A Shares and Consolidated Class B Shares resulting from the share consolidation will not be issued to the shareholders of the Company and instead, any fractional shares that would have resulted from the share consolidation will be rounded up to the next whole number; and (D) the Board be authorized and directed to do all such acts and things as it may consider necessary or desirable for the purpose of effectuating the share consolidation, including determining the definitive ratio and the effective date of the share consolidation and any other changes to the Company’s authorized share capital in connection with and as necessary to effect the share consolidation.

On August 6, 2026, the Board approved unanimously a share consolidation at the ratio of forty (40)-for-one (1) (the “Share Consolidation” or the “Reverse Stock Split”), to be effective on October 23, 2026 (the “Effective Date”), pursuant to which, on the Effective Date, each 40 issued and unissued class A ordinary shares will be automatically combined into one class A ordinary share, and each 40 issued and unissued class B ordinary shares will be automatically combined into one class B ordinary share. Following the Share Consolidation, the par value of each class A ordinary share and each class B ordinary share will be changed from $0.0000625 to $0.0025. All fractional shares resulting from the Share Consolidation will not be issued to shareholders; instead, any fractional entitlements will be rounded up to the next whole number.

As of the date hereof, the Company has 112,867,000 class A ordinary shares and 12,250,000 class B ordinary shares issued and outstanding. Following the share consolidation, the Company expects to have approximately 2,821,675 class A ordinary shares and 306,250 class B ordinary shares issued and outstanding, subject to adjustment for the rounding up of fractional shares. The new CUSIP number for the Company’s class A ordinary shares following the reverse stock split will be G5880S139.

In connection with the Share Consolidation, the Company amended and restated its memorandum and articles of association currently in effect to reflect the adjustment of the number of authorized ordinary shares, the number of class A ordinary shares and class B ordinary shares of the Company and the par value. As advised by our Cayman Islands counsel, Appleby, the Share Consolidation and the third amended and restated memorandum and articles of association may need to be approved and ratified by shareholders at a general meeting.

About Ping An Biomedical Co., Ltd

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

CONTACT: For more information, please contact:

Ping An Biomedical Co., Ltd.

Email: corpsec@pingan365.vip

Celestia Investor Relations

Email: investors@celestiair.com

Expansion extends Alignment’s Nevada presence to three counties, home to more than 554,000 Medicare beneficiaries

LAS VEGAS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced it will expand into Nye County beginning Jan. 1, 2027, offering new Medicare Advantage plan options to local seniors. With the expansion, Alignment Health Plan will serve Clark, Nye and Washoe counties, which are home to more than 554,000 Medicare beneficiaries, according to the Centers for Medicare & Medicaid Services (CMS) data¹.

With the addition of Nye County, Alignment Health’s 2027 Nevada portfolio features six Medicare Advantage plans across three counties supported by more than 6,500 physicians and access to premier provider partners. People with Medicare living in the service area can choose from a co-branded plan with Intermountain Health, plans with Instacart, a plan that helps reduce their Medicare Part B premium and specialized plans for people living with diabetes or heart conditions.

“Choosing the right Medicare coverage and getting the care you need shouldn’t be a challenge,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “We’re excited to expand into Nye County and serve more Nevada seniors with the kind of care and support that treats them as people, not policies. By connecting members to trusted local providers and personalized guidance, we can help them spend less time navigating the health care system and more time focusing on what matters most: staying healthy, independent and engaged in their communities.”

Building on Trusted Nevada Provider Relationships

Members have access to nearby primary care providers, specialists and hospitals through health systems and medical groups in Clark, Nye and Washoe counties.

• Intermountain Health in Clark and Nye counties. Through Alignment’s relationship with Intermountain Health, members in Clark and Nye counties have access to coordinated care delivered through one of the region’s leading healthcare systems, including senior-focused primary care, specialty care, urgent care and telehealth services.
• Trusted local providers. Clark County members can also see providers from The Valley Health System, University Medical Center, Dignity Health and UNLV Health, and Washoe County members have access to providers from Prime Healthcare and Pinnacle Medical Group, among others.

Proven Quality and Member Experience

For 2027, Alignment’s Nevada HMO contract is rated 4 out of 5 stars, and its HMO contract that includes the Clark County Platinum + Instacart and Smart plans is rated 4.5 out of 5 stars. Medicare evaluates plans annually using a 5-star rating system to help consumers compare quality and performance, with higher ratings reflecting strong performance across measures such as member experience, customer service and care coordination.

More Choice and Support for Nevada Seniors

Alignment Health’s 2027 Medicare Advantage plans are designed to help Nevada seniors find coverage that fits their health needs, budget and lifestyle. Alignment Health + Intermountain Health (HMO), available in Clark and Nye counties, lowers its out-of-pocket maximum for 2027. In Clark County, Alignment Health Platinum + Instacart (HMO) includes a quarterly grocery allowance on Instacart for qualifying members, and Alignment Health Smart (HMO) helps reduce members’ Medicare Part B premium.

Members living with diabetes or heart conditions can choose Heart & Diabetes (HMO C-SNP) in Clark and Washoe counties, with up to $204 monthly Essentials allowance for eligible groceries and everyday health-related expenses².

All members have access to Alignment’s 24/7 concierge team for personalized support, including help understanding their benefits, finding the right doctor, coordinating care and receiving answers when they need them. Depending on the plan, members may also enjoy benefits such as $0 copays on more than 10,000 prescribed medications, over-the-counter and grocery² allowances, fitness programs and in-home support.

Medicare’s Annual Enrollment Period runs Oct. 15 through Dec. 7, 2026, with coverage taking effect Jan. 1, 2027. To learn more about Alignment Health’s 2027 Medicare Advantage plans in Nevada, visit alignmenthealthplan.com or call 1-888-979-2247.³

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Media Contact:
Jerry Slowey
publicrelations@ahcusa.com

Y0141_27444EN_M

¹ Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2026 MA State/County Penetration
² Special supplemental benefits for the chronically ill (SSBCI)-qualifying chronic conditions include congestive heart failure (CHF), dementia, diabetes, and stroke. Other chronic conditions may apply. Medical records will be used to establish the member qualification. The benefits mentioned are a part of a special supplemental program for the chronically ill. Not all members qualify because other eligibility and coverage criteria also apply.
³ Alignment Health Plan is an HMO, HMO POS, HMO C-SNP, HMO D-SNP and PPO plan with a Medicare contract and a contract with the California, Nevada, North Carolina and Texas Medicaid programs. Enrollment in Alignment Health Plan depends on contract renewal. The benefit information provided is a summary, not a complete description of benefits. For more information, contact the plan. Call 1-888-979-2247 (TTY: 711), 8 a.m. to 8 p.m. Monday through Friday, for more information. Other providers are available in our network.

• Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,¹ a common inflammatory rheumatic disease with limited advanced treatment options^2-6
• Approval based on Phase III REPLENISH trial showing Cosentyx doubled sustained remission rates vs placebo at Week 52; safety results consistent with established Cosentyx profile⁷
• Additional regulatory reviews of Cosentyx in PMR ongoing globally, including in US and Japan

Basel, October 21, 2026 – Novartis announced today that the European Commission (EC) has approved Cosentyx^® (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper. With this approval, Cosentyx becomes the first and only interleukin-17A (IL-17A) inhibitor approved in Europe for adults with PMR.¹

PMR is a common inflammatory rheumatic disease in adults aged over 50, characterized by acute pain and stiffness in the shoulders, neck, and hips.² It is particularly prevalent among people of Northern European descent.² Despite the considerable burden of symptoms on patients, advanced treatment options have remained limited.^2–6 The current standard of care involves prolonged steroid use, which is associated with high relapse rates and significant adverse outcomes.^2–6

“The approval of secukinumab marks an important advancement for people living with PMR and has the potential to transform how we manage this disease beyond prolonged steroid use alone,” said Prof. Christian Dejaco, Director, Department of Rheumatology, South Tyrol Health Trust, Bruneck, Italy. “Its ability to help patients achieve sustained disease control while tapering steroids, together with its established safety profile, may help address a longstanding challenge in PMR care.”

Supported by data from the Phase III REPLENISH trial, the Cosentyx recommended dose for adults with PMR is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing, in combination with a tapering course of glucocorticoids, after which Cosentyx can be continued as monotherapy. Based on clinical response, the maintenance dose can be increased to 300 mg.^7,8

“People living with PMR need treatment options that can help deliver lasting disease control, prevent relapses and support better long-term outcomes,” said Patrick Horber, President, International, Novartis. “The approval of Cosentyx in PMR marks an important step forward for patients who continue to face significant challenges with long-term disease management. This milestone adds to the meaningful progress Cosentyx has already brought to many people living with immune-mediated diseases.”

About Cosentyx
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases.⁹ It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and hidradenitis suppurativa (HS).^9–11 Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and juvenile AS.^9–16

About the REPLENISH trial
The REPLENISH trial (NCT05767034) is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted across 27 countries, evaluating the efficacy and safety of Cosentyx in patients with polymyalgia rheumatica (PMR). Patients were randomized into three treatment arms: Cosentyx 300 mg, Cosentyx 150 mg, or placebo, all in combination with a 24-week steroid taper regimen. The primary endpoint of the trial was to assess whether Cosentyx 300 mg s.c. plus a 24-week steroid taper is superior to placebo plus a 24-week steroid taper in achieving sustained remission at Week 52. Key secondary endpoints included the proportion of patients achieving complete sustained remission at Week 52, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through Week 52.¹⁷

About polymyalgia rheumatica (PMR)
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.² Relapses are frequent, affecting up to 40% of patients in the first year.⁴ Long-term steroid use is the current standard of care and carries significant risks, including osteoporosis and diabetes.¹⁸ Beyond physical complications, PMR substantially impairs quality of life through pain, fatigue, restricted mobility, and fear of relapse.^4,19,20

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex, and often overlooked autoimmune and immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. European Medicines Agency. Search results for “polymyalgia rheumatica.” European Medicines Agency. https://www.ema.europa.eu/en/search?search_api_fulltext=polymyalgia%20rheumatica [Last Accessed: October 2026].
2. Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Polymyalgia rheumatica. Lancet. 2023;402(10411):1459–1472.
3. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873–1878.
4. Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheum. 2022;41(1):19–31.
5. Regeneron Pharmaceuticals, Inc.; Sanofi. Kevzara® (sarilumab) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf [Last Accessed: October 2026].
6. European Medicines Agency. Kevzara: EPAR product information. https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf [Last Accessed: October 2026].
7. Stone JH, Buttgereit F, Saraux A, et al. Secukinumab in polymyalgia rheumatica. N Eng J Med. 2026;395(7):637–647.
8. Dejaco C, et al. Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial. Oral presentation presented at European Congress of Rheumatology (EULAR) 2026; June 3–6, 2026; London, UK. #OP0116.
9. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724.
10. Novartis Europharm Limited. Cosentyx^® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last Accessed: October 2026].
11. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last Accessed: October 2026].
12. Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis [Last Accessed: October 2026].
13. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last Accessed: October 2026].
14. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last Accessed: October 2026].
15. Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa [Last Accessed: October 2026].
16. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf [Last Accessed: October 2026].
17. ClinicalTrials.gov. Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH). NCT05767034. Available at: https://clinicaltrials.gov/study/NCT05767034 [Last Accessed: October 2026].
18. Mazzantini M, Torre C, Miccoli M, et al. Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study. J Rheum. 2012;39(3):552–557.
19. Hutchings A, Hollywood J, Lamping DL, et al. Clinical Outcomes, Quality of Life, and Diagnostic Uncertainty in the First Year of Polymyalgia Rheumatica. Arthritis Rheum. 2007;57(5):803–809.
20. Mackie SL, Arun P, Padmanabhan V, et al. Patient perspectives on life impact and unmet needs in giant cell arteritis and polymyalgia rheumatica: insights from social media. Rheumatol Adv Pract. 2025;10(1):rkaf140.

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.

An audio replay of the call will be available through Wednesday, November 11, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.

A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.

About Progyny

Progyny is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx^®, and personalized guidance from Progyny Care Advocates^® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

For Further Information, Please Contact:
Investors:
James Hart
investors@progyny.com

Media:
Alexis Ford
media@progyny.com

Exclusive boutique community offers luxury homes on estate-sized home sites along the Saluda River

PIEDMONT, S.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Waterford Pointe, an intimate community of 28 luxury homes on expansive wooded home sites adjacent to the Saluda River in the Piedmont area of Powdersville, South Carolina. The Sales Center is now open at 201 Waterford Pointe Drive in Piedmont.

Waterford Pointe features luxury single-family home designs ranging from 3,645 to 4,680+ square feet with 4 to 5 bedrooms and 3.5 to 5.5 bathrooms. These exquisite homes are situated on expansive, estate-sized home sites of up to three acres, with some offering beautiful water views of the Saluda River. Homes are priced from the upper $800,000s.

“Waterford Pointe offers home shoppers an exclusive opportunity to own a luxury home in an unmatched setting with access to the natural beauty of the Saluda River and downtown Greenville just 10 miles away,” said Jason Simpson, Group President of Toll Brothers in South Carolina. “With estate-sized home sites, thoughtfully designed floor plans, and personalization options available at the Toll Brothers Design Studio, this community exemplifies the Toll Brothers luxury lifestyle in South Carolina.”

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

Residents of Waterford Pointe will enjoy a gated community setting adjacent to the Saluda River and proximity to everyday conveniences, local transit, and downtown Greenville located just 10 miles away. The community is also assigned to the highly regarded Anderson School District One, making it ideal for families seeking top-rated public schools.

For more information on Waterford Pointe by Toll Brothers, or to schedule an appointment, call 866-232-1717 or visit TollBrothers.com/SC.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7045de7-ecf0-43b2-8915-f50be3ec6265

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

CATSKILL, N.Y., Oct. 21, 2026 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (NASDAQ-GCBC) today announced that its Board of Directors has approved a quarterly cash dividend of $0.11 per share on the Company’s common stock. The dividend reflects an annual cash dividend rate of $0.44 per share, which is the same rate as the dividend declared during previous quarter.

The cash dividend for the quarter ended September 30, 2026, will be paid to shareholders of record as of November 13, 2026, and is expected to be paid on November 27, 2026.

The Company is the majority-owned subsidiary of Greene County Bancorp, MHC (the “MHC”), a federal mutual holding company, which owns 54.1% of the Company’s outstanding common shares. The MHC is waiving its receipt of this dividend. The MHC received the nonobjection of the Federal Reserve Bank of Philadelphia to waive its right to receive dividends, aggregating up to $0.64 per share, paid by the Company for the four quarters ending March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.

Greene County Bancorp, Inc. is the holding company for Bank of Greene (formerly the Bank of Greene County), and its subsidiary Greene County Commercial Bank. The Company is the leading provider of community-based banking services throughout the Hudson Valley and Capital Regions of New York State. Its customers include individuals, businesses, municipalities and other institutions. Greene County Bancorp, Inc. (GCBC) is publicly traded on the Nasdaq Capital Market and is dedicated to promoting economic development and a high quality of life in the communities it serves. For more information on Greene County Bancorp, Inc., visit www.bankofgreene.com.

For Further Information Contact:
Donald E. Gibson
President and Chief Executive Officer
(518) 943-2600
donaldg@bankofgreene.com

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	easyJet plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	20/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	27 2/7p ordinary (ISIN-GB00B7KR2P84)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	20,105,805	2.65%
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	20,105,805	2.65%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
27 2/7p ordinary	CFD	Increasing a long position	342,075	GBP 6.8139

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	21/10/2026
Contact name:	Alex McMillan
Telephone number:	646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.